# Vicarious Surgical Inc.: financial statements, quarterly

RBOT · OTC · CIK 1812173 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rbot.md) · [Financials](/companies/rbot/financials.md) · [Filings](/companies/rbot/filings.md) · [Insiders](/companies/rbot/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rbot/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.4](/filings/0001213900-24-037265.md) | [12.7](/filings/0001213900-24-067807.md) | [13.0](/filings/0001213900-24-096886.md) | [8.5 d](/filings/0001213900-25-024588.md) | [10.0](/filings/0001213900-25-042087.md) | [10.9](/filings/0001213900-25-075049.md) | [10.8](/filings/0001213900-25-109320.md) | [8.5 d](/filings/0001213900-26-025189.md) | [9.4](/filings/0001213900-25-042087.md) | [9.1](/filings/0001213900-25-075049.md) | [8.0](/filings/0001213900-25-109320.md) | [7.1 d](/filings/0001213900-26-025189.md) |
| Operating income | $m | [(22.3)](/filings/0001213900-24-037265.md) | [(21.5)](/filings/0001213900-24-067807.md) | [(21.4)](/filings/0001213900-24-096886.md) | [(15.5) d](/filings/0001213900-25-024588.md) | [(16.1)](/filings/0001213900-25-042087.md) | [(17.7)](/filings/0001213900-25-075049.md) | [(17.8)](/filings/0001213900-25-109320.md) | [(15.0) d](/filings/0001213900-26-025189.md) | [(15.7)](/filings/0001213900-25-042087.md) | [(13.5)](/filings/0001213900-25-075049.md) | [(11.5)](/filings/0001213900-25-109320.md) | [(9.3) d](/filings/0001213900-26-025189.md) |
| Interest expense | $m | [0.0](/filings/0001213900-24-037265.md) | [0.0](/filings/0001213900-24-067807.md) | [0.0](/filings/0001213900-23-086210.md) | [0.0 d](/filings/0001213900-24-019594.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(26.9)](/filings/0001213900-24-037265.md) | [(15.3)](/filings/0001213900-24-067807.md) | [(15.7)](/filings/0001213900-24-096886.md) | [(13.1) d](/filings/0001213900-25-024588.md) | [(17.0)](/filings/0001213900-25-042087.md) | [(15.2)](/filings/0001213900-25-075049.md) | [(17.1)](/filings/0001213900-25-109320.md) | [(13.9) d](/filings/0001213900-26-025189.md) | [(15.4)](/filings/0001213900-25-042087.md) | [(13.2)](/filings/0001213900-25-075049.md) | [(11.1)](/filings/0001213900-25-109320.md) | [(10.5) d](/filings/0001213900-26-025189.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001213900-24-037265.md) | [(3.62)](/filings/0001213900-24-067807.md) | [(0.10)](/filings/0001213900-23-086210.md) | not reported | [(0.10)](/filings/0001213900-24-037265.md) | [(2.59)](/filings/0001213900-24-067807.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.21)](/filings/0001213900-24-037265.md) | [(3.62)](/filings/0001213900-24-067807.md) | [(0.10)](/filings/0001213900-23-086210.md) | not reported | [(0.10)](/filings/0001213900-24-037265.md) | [(2.59)](/filings/0001213900-24-067807.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.1](/filings/0001213900-23-037375.md) | [32.8](/filings/0001213900-23-060398.md) | [59.1](/filings/0001213900-23-086210.md) | [52.8](/filings/0001213900-25-024588.md) | [38.2](/filings/0001213900-24-037265.md) | [20.3](/filings/0001213900-24-067807.md) | [7.1](/filings/0001213900-24-096886.md) | [9.7](/filings/0001213900-26-025189.md) | [2.6](/filings/0001213900-25-042087.md) | [3.9](/filings/0001213900-25-075049.md) | [3.2](/filings/0001213900-25-109320.md) | [2.6](/filings/0001213900-26-025189.md) |
| Current assets | $m | [101](/filings/0001213900-23-037375.md) | [85.3](/filings/0001213900-23-060398.md) | [113](/filings/0001213900-23-086210.md) | [101](/filings/0001213900-25-024588.md) | [87.1](/filings/0001213900-24-037265.md) | [75.9](/filings/0001213900-24-067807.md) | [64.0](/filings/0001213900-24-096886.md) | [51.7](/filings/0001213900-26-025189.md) | [39.7](/filings/0001213900-25-042087.md) | [26.1](/filings/0001213900-25-075049.md) | [15.1](/filings/0001213900-25-109320.md) | [11.6](/filings/0001213900-26-025189.md) |
| Total assets | $m | [121](/filings/0001213900-23-037375.md) | [105](/filings/0001213900-23-060398.md) | [132](/filings/0001213900-23-086210.md) | [120](/filings/0001213900-25-024588.md) | [105](/filings/0001213900-24-037265.md) | [93.3](/filings/0001213900-24-067807.md) | [80.6](/filings/0001213900-24-096886.md) | [67.7](/filings/0001213900-26-025189.md) | [55.1](/filings/0001213900-25-042087.md) | [40.9](/filings/0001213900-25-075049.md) | [29.3](/filings/0001213900-25-109320.md) | [19.6](/filings/0001213900-26-025189.md) |
| Current liabilities | $m | [6.7](/filings/0001213900-23-037375.md) | [7.5](/filings/0001213900-23-060398.md) | [7.8](/filings/0001213900-23-086210.md) | [7.3](/filings/0001213900-25-024588.md) | [5.1](/filings/0001213900-24-037265.md) | [7.2](/filings/0001213900-24-067807.md) | [8.6](/filings/0001213900-24-096886.md) | [7.7](/filings/0001213900-26-025189.md) | [7.9](/filings/0001213900-25-042087.md) | [5.1](/filings/0001213900-25-075049.md) | [3.2](/filings/0001213900-25-109320.md) | [3.9](/filings/0001213900-26-025189.md) |
| Total liabilities | $m | [33.4](/filings/0001213900-23-037375.md) | [28.8](/filings/0001213900-23-060398.md) | [24.2](/filings/0001213900-23-086210.md) | [21.9](/filings/0001213900-25-024588.md) | [21.3](/filings/0001213900-24-037265.md) | [21.5](/filings/0001213900-24-067807.md) | [22.7](/filings/0001213900-24-096886.md) | [21.0](/filings/0001213900-26-025189.md) | [21.0](/filings/0001213900-25-042087.md) | [17.8](/filings/0001213900-25-075049.md) | [15.3](/filings/0001213900-25-109320.md) | [9.7](/filings/0001213900-26-025189.md) |
| Long-term debt | $m | not reported | not reported | not reported | [2.0](/filings/0001213900-24-019594.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [87.7](/filings/0001213900-24-067807.md) | [75.7](/filings/0001213900-24-096886.md) | [108](/filings/0001213900-24-096886.md) | [98.0](/filings/0001213900-26-025189.md) | [84.0](/filings/0001213900-25-075049.md) | [71.9](/filings/0001213900-25-109320.md) | [57.9](/filings/0001213900-25-109320.md) | [46.7](/filings/0001213900-26-025189.md) | [34.1](/filings/0001213900-25-075049.md) | [23.1](/filings/0001213900-25-109320.md) | [14.1](/filings/0001213900-25-109320.md) | [9.8](/filings/0001213900-26-025189.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.6)](/filings/0001213900-24-037265.md) | [(15.1) d](/filings/0001213900-24-067807.md) | [(17.3) d](/filings/0001213900-24-096886.md) | [(11.4) d](/filings/0001213900-25-024588.md) | [(14.5)](/filings/0001213900-25-042087.md) | [(11.0) d](/filings/0001213900-25-075049.md) | [(12.7) d](/filings/0001213900-25-109320.md) | [(11.8) d](/filings/0001213900-26-025189.md) | [(11.8)](/filings/0001213900-25-042087.md) | [(13.5) d](/filings/0001213900-25-075049.md) | [(10.5) d](/filings/0001213900-25-109320.md) | [(9.3) d](/filings/0001213900-26-025189.md) |
| Capital expenditure | $m | [0.3](/filings/0001213900-24-037265.md) | [0.2 d](/filings/0001213900-24-067807.md) | [0.1 d](/filings/0001213900-23-086210.md) | [1.0 d](/filings/0001213900-25-024588.md) | [0.0](/filings/0001213900-25-042087.md) | [0.0 d](/filings/0001213900-25-075049.md) | not reported | not reported | [0.0](/filings/0001213900-25-042087.md) | [0.0 d](/filings/0001213900-25-075049.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [128](/filings/0001213900-23-037375.md) | [121](/filings/0001213900-23-060398.md) | [122](/filings/0001213900-23-086210.md) | [126](/filings/0001213900-24-037265.md) | [4.2](/filings/0001213900-24-067807.md) | [5.2](/filings/0001213900-24-096886.md) | [5.9](/filings/0001213900-25-042087.md) | [5.9](/filings/0001213900-25-075049.md) | [5.9](/filings/0001213900-25-109320.md) | [5.9](/filings/0001213900-25-042087.md) | [5.9](/filings/0001213900-25-075049.md) | [6.0](/filings/0001213900-25-109320.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.